AR and hepatocellular carcinoma: In addition, they also indicate that the AR-CCRK-β-catenin-positive regulatory circuit might be a target of intense interest to elaborate novel therapeutic approaches in future, especially in male-predominant malignant tumors such as HBV-related HCC.